These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 21342558)

  • 1. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.
    John S; Thangapandian S; Sakkiah S; Lee KW
    BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High throughput virtual screening and E-pharmacophore filtering in the discovery of new BACE-1 inhibitors.
    Muthusamy K; Singh KhD; Chinnasamy S; Nagamani S; Krishnasamy G; Thiyagarajan C; Premkumar P; Anusuyadevi M
    Interdiscip Sci; 2013 Jun; 5(2):119-26. PubMed ID: 23740393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-silico Studies and Biological Activity of Potential BACE-1 Inhibitors.
    Arya R; Paliwal S; Gupta SP; Sharma S; Madan K; Mishra A; Verma K; Chauhan N
    Comb Chem High Throughput Screen; 2021; 24(5):729-736. PubMed ID: 32957879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors.
    Razzaghi-Asl N; Firuzi O; Hemmateenejad B; Javidnia K; Edraki N; Miri R
    Bioorg Med Chem; 2013 Nov; 21(22):6893-909. PubMed ID: 24113238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
    Kumar A; Roy S; Tripathi S; Sharma A
    J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemometric design to explore pharmacophore features of BACE inhibitors for controlling Alzheimer's disease.
    Hossain T; Mukherjee A; Saha A
    Mol Biosyst; 2015 Feb; 11(2):549-57. PubMed ID: 25435329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore based 3D-QSAR modeling, virtual screening and docking for identification of potential inhibitors of β-secretase.
    Palakurti R; Vadrevu R
    Comput Biol Chem; 2017 Jun; 68():107-117. PubMed ID: 28288354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features.
    Shimmyo Y; Kihara T; Akaike A; Niidome T; Sugimoto H
    Biochim Biophys Acta; 2008 May; 1780(5):819-25. PubMed ID: 18295609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease.
    Kumar A; Srivastava G; Sharma A
    Comput Biol Chem; 2017 Dec; 71():1-9. PubMed ID: 28950235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review.
    Gehlot P; Kumar S; Kumar Vyas V; Singh Choudhary B; Sharma M; Malik R
    Bioorg Med Chem; 2022 Nov; 74():117047. PubMed ID: 36265268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.
    Wang YS; Strickland C; Voigt JH; Kennedy ME; Beyer BM; Senior MM; Smith EM; Nechuta TL; Madison VS; Czarniecki M; McKittrick BA; Stamford AW; Parker EM; Hunter JC; Greenlee WJ; Wyss DF
    J Med Chem; 2010 Feb; 53(3):942-50. PubMed ID: 20043700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational methods in the discovery and design of BACE-1 inhibitors.
    Kacker P; Bottegoni G; Cavalli A
    Curr Med Chem; 2012; 19(36):6095-111. PubMed ID: 23072352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors.
    Huang W; Yu H; Sheng R; Li J; Hu Y
    Bioorg Med Chem; 2008 Dec; 16(24):10190-7. PubMed ID: 19013073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis and Evaluation of 2,4,6-substituted Pyrimidine Derivatives as BACE-1 Inhibitor: Plausible Lead for Alzheimer's Disease.
    Jain P; Wadhwa PK; Jadhav HR
    Med Chem; 2021; 17(10):1194-1206. PubMed ID: 33349218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of natural product vs neurodegenerative disorders: In silico study of artoflavanocoumarin as BACE-1 inhibitor.
    Razzaghi-Asl N; Karimi A; Ebadi A
    Comput Biol Chem; 2018 Dec; 77():307-317. PubMed ID: 30445338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress toward the discovery and development of efficacious BACE inhibitors.
    Durham TB; Shepherd TA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic BACE-1 Inhibitor Administration in TASTPM Mice (APP KM670/671NL and PSEN1 M146V Mutation): An EEG Study.
    Lopez S; Del Percio C; Forloni G; Frasca A; Drinkenburg WH; Lizio R; Noce G; Ferri R; Soricelli A; Stocchi F; Vacca L; Bordet R; Richardson JC; Babiloni C
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Aβ secretion by human neurons under conditions of strongly increased BACE activity.
    Scholz D; Chernyshova Y; Ückert AK; Leist M
    J Neurochem; 2018 Oct; 147(2):256-274. PubMed ID: 29804308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
    Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
    Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.